| scholarly article | Q13442814 |
| P356 | DOI | 10.3233/JAD-170045 |
| P8608 | Fatcat ID | release_jv3j4bdky5c5fjr4tgs4ywaq54 |
| P698 | PubMed publication ID | 28304309 |
| P50 | author | Sandra Villegas | Q37370937 |
| P2093 | author name string | Gisela Esquerda-Canals | |
| Laia Montoliu-Gaya | |||
| Jofre Güell-Bosch | |||
| P2860 | cites work | Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 |
| Alzheimer's Disease | Q22248111 | ||
| Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 | ||
| Positional cloning of the mouse obese gene and its human homologue | Q22251285 | ||
| Alzheimer mechanisms and therapeutic strategies | Q22252311 | ||
| Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy | Q24604376 | ||
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain | Q27003253 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways | Q28081678 | ||
| Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium | Q28252389 | ||
| Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy | Q28282855 | ||
| Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E | Q28508278 | ||
| The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease | Q28610089 | ||
| The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes) | Q28714850 | ||
| Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 | ||
| Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 | ||
| The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics | Q29614972 | ||
| Intracellular amyloid-beta in Alzheimer's disease | Q29615626 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Identification and expression cloning of a leptin receptor, OB-R | Q29620255 | ||
| Apolipoprotein E and Sex Bias in Cerebrovascular Aging of Men and Mice | Q31122715 | ||
| Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system | Q33262322 | ||
| Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females | Q33563135 | ||
| Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways | Q34005022 | ||
| Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism | Q34144158 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies | Q34219001 | ||
| Size matters: use of YACs, BACs and PACs in transgenic animals | Q34220676 | ||
| Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu | Q34400140 | ||
| Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes | Q34452028 | ||
| Apolipoprotein E: From lipid transport to neurobiology | Q34497951 | ||
| Modeling Alzheimer's disease in transgenic rats | Q34508624 | ||
| A reliable way to detect endogenous murine β-amyloid | Q34577192 | ||
| Gene therapy using adeno-associated virus vectors | Q34852719 | ||
| The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism | Q35578655 | ||
| Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice | Q35809803 | ||
| The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease | Q36381073 | ||
| Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide | Q36384642 | ||
| Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology | Q36724967 | ||
| Reassessing the amyloid cascade hypothesis of Alzheimer's disease | Q37187966 | ||
| Transgenesis by means of blastocyst-derived embryonic stem cell lines | Q37409515 | ||
| Recent rodent models for Alzheimer's disease: clinical implications and basic research | Q37956513 | ||
| Mouse models of Alzheimer's disease | Q37964886 | ||
| Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease | Q38097859 | ||
| New animal models of Alzheimer's disease that display insulin desensitization in the brain | Q38164626 | ||
| Genetic mouse models of brain ageing and Alzheimer's disease | Q38173230 | ||
| Animal models of dementia and cognitive dysfunction | Q38234442 | ||
| Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel? | Q38366757 | ||
| FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction | Q40737559 | ||
| Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease | Q40849918 | ||
| Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides | Q41172424 | ||
| Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon | Q42084058 | ||
| Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology | Q42655700 | ||
| Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case | Q43449419 | ||
| Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). | Q43825281 | ||
| Reconstitution of gamma-secretase activity | Q44393107 | ||
| Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68. | Q46011081 | ||
| Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. | Q48404445 | ||
| Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior | Q48493843 | ||
| The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells | Q48857702 | ||
| Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. | Q48933018 | ||
| The physiology of obese-hyperglycemic mice [ob/ob mice]. | Q54970328 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 1171-1183 | |
| P577 | publication date | 2017-03-10 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Mouse Models of Alzheimer's Disease. | |
| P478 | volume | 57 |
| Q91718211 | A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease |
| Q91045286 | Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease |
| Q38657904 | Anti-Oxidative Stress Activity Is Essential for Amanita caesarea Mediated Neuroprotection on Glutamate-Induced Apoptotic HT22 Cells and an Alzheimer's Disease Mouse Model |
| Q98471333 | Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice |
| Q38659874 | Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology |
| Q93000628 | Intracellular Calcium Dysregulation by the Alzheimer's Disease-Linked Protein Presenilin 2 |
| Q89493870 | Kaixinsan, a Well-Known Chinese Herbal Prescription, for Alzheimer's Disease and Depression: A Preclinical Systematic Review |
| Q92483746 | Modeling Alzheimer's disease with iPSC-derived brain cells |
| Q90162258 | Overview of Transgenic Mouse Models for Alzheimer's Disease |
| Q64056852 | Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease |
| Q92662873 | Quercetin in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies |
| Q55365674 | Sex Differences in Healthspan Predict Lifespan in the 3xTg-AD Mouse Model of Alzheimer's Disease. |
| Q94593309 | Sodium Butyrate Protects N2a Cells against Aβ Toxicity In Vitro |
| Q46257963 | Studies for Improving a Rat Model of Alzheimer's Disease: Icv Administration of Well-Characterized β-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory. |
| Q58698284 | The McGill Transgenic Rat Model of Alzheimer's Disease Displays Cognitive and Motor Impairments, Changes in Anxiety and Social Behavior, and Altered Circadian Activity |
| Q89948704 | The multiplex model of the genetics of Alzheimer's disease |
| Q98289131 | Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa |
| Q51760891 | Understanding Epigenetics in the Neurodegeneration of Alzheimer's Disease: SAMP8 Mouse Model. |
| Q89596058 | Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk |
| Q92698961 | Wnt Signaling Deregulation in the Aging and Alzheimer's Brain |
Search more.